TRACON Pharmaceuticals (NASDAQ:TCON) Stock Crosses Below 50 Day Moving Average of $0.36

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)’s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.36 and traded as low as $0.06. TRACON Pharmaceuticals shares last traded at $0.07, with a volume of 3,059 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TCON shares. HC Wainwright reissued a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st. StockNews.com started coverage on shares of TRACON Pharmaceuticals in a report on Tuesday. They issued a “hold” rating for the company.

TRACON Pharmaceuticals Stock Performance

The stock has a fifty day moving average of $0.36 and a 200-day moving average of $2.25. The company has a market cap of $252,340.00, a PE ratio of 0.11 and a beta of 1.35.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Announces Dividend

The firm also recently announced a dividend, which was paid on Monday, July 8th. Shareholders of record on Friday, June 28th were issued a dividend of $0.045 per share. This represents a yield of 40.3%. The ex-dividend date was Thursday, June 27th.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.